Supplementary Figure Legends

Supplementary Figure 1. Effect of 10 μm norepinephrine on FAK phosphorylation at the various tyrosine sites in the SKOV3ip1 cells.

Supplementary Figure 2. (a-b) Effect of 10 μm norepinephrine on $pFAK^{Y397}$ over time.

Supplementary Figure 3. Western blot of lysate collected after transfection with FAK siRNA. Quantification of band intensity relative to actin intensity is shown below the Western blot.

Supplementary Figure 4. Effect of norepinephrine (10uM) in presence or absence of specific beta blockers.

Supplementary Figure 5. a) Western blot of lysate collected after transfection with either ADRB1 or ADRB2 siRNA. b) Effect of 10 μM dobutamine in the presence of control or ADRB1 siRNA on PKA activity.

Supplementary Figure 6. Effect of 10 μm norepinephrine on $pFAK^{Y397}$ in the presence or absence of α1 (prazosin) or α2 (yohimbine) antagonists in SKOV3ip1 (a) and EG (b) cells. In panels (a-b), the immunoblot is shown at the top and quantification of band intensity relative to total FAK intensity is shown below.

Supplementary Figure 7. Effect of 10 μm norepinephrine on SKOV3ip1 anoikis with or without α1 (prazosin) or α2 (yohimbine) antagonists. Results represent the mean ± s.e.m. *$p<0.01$.

Supplementary Figure 8. Effect of 10 μM norepinephrine on SKOV3ip1 anoikis in presence or absence of specific beta blockers. Results represent the mean ± s.e.m. *$p<0.01$.

Supplementary Figure 9. a) Effect of 10 μm norepinephrine on anoikis in ADRB-negative A2780-Par and RMG-II cells. b) Effect of isoprotenerol on anoikis following transfection of RMG-II cells with either ADRB2 (RMG-II-ADRB2) or empty vector (RMG-II-neo). Results represent the mean ± s.e.m. *$p<0.05$

Supplementary Figure 10. *In vitro* kinase assay with Src and either FAK or kinase-dead FAK (mutation at K454M). The kinase assay was also performed in the presence or absence of a Src inhibitor (AP23846).

Supplementary Figure 11. Effect of 10 μM norepinephrine on FAK phosphorylation at the various tyrosine sites in the SYF-null fibroblasts.

Supplementary Figure 12. Western blot of lysate obtained from orthotopic SKOV3ip1 tumors harvested from mice with or without daily restraint stress.

Supplementary Figure 13. Western blot of tumors harvested from animals treated with either DOPC liposomes, control siRNA-DOPC, or FAK siRNA-DOPC. Quantification of band intensity relative to actin intensity is shown below the Western blot.

Supplementary Figure 14. Western blot of SKOV3ip1 tumors harvested from animals treated with either control siRNA-DOPC or Src siRNA-DOPC. Quantification of band intensity of $pFAK^{Y397}$ relative to actin intensity is shown below the Western blot.

Supplementary Figure 15. Kaplan-Meier curve of disease-specific mortality for patients with epithelial ovarian carcinoma based on $pFAK^{Y397}$ scores normalized to total FAK levels.

Supplementary Figure 16. Box-Plot of FAK and $pFAK^{Y397}$ scores based on CESD scores ≥16 or tumoral norepinephrine (NE) levels (greater *versus* less than median value of 0.84 pg/mg).

Supplementary Figure 1



Supplementary Figure 2



Supplementary Figure 3



Supplementary Figure 4



Supplementary Figure 5



Supplementrary Figure 6



Supplementary Figure 7



Supplementary Figure 8



Supplementary Figure 9

a



b



Supplementary Figure 10



Supplementary Figure 11



Supplementary Figure 12



Supplementary Figure 13



Supplementary Figure 14



Supplemental Fig 15



Supplemental Fig 16